Do analysts rate CYPH or ACIU?

AC Immune has a consensus target price of $7.50, suggesting a potential upside of 194.70%. Given AC Immune's stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AC Immune 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable earnings & valuation, GALT or CYPH?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A

Is GALT or CYPH more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Cypherpunk Technologies N/A -48.33% -42.21%

Do analysts prefer CYPH or FBRX?

Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 218.59%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Forte Biosciences is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Forte Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings and valuation, CYPH or FBRX?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A Forte Biosciences N/A N/A -$69.38M -$4.64 N/A

Is CYPH or FBRX more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Forte Biosciences N/A -106.17% -85.50%

Do analysts prefer CYPH or FULC?

Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 115.79%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Fulcrum Therapeutics 4 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is CYPH or FULC more profitable?

Fulcrum Therapeutics' return on equity of -27.80% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Fulcrum Therapeutics N/A -27.80% -26.32%

Is IKT or CYPH more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Cypherpunk Technologies N/A -48.33% -42.21%

Cypherpunk Technologies (CYPH) Competitors

$0.64 +0.02 (+3.12%)

As of 06/26/2026 03:57 PM Eastern

Compare

CYPH vs. ACIU, GALT, FBRX, FULC, and IKT

Should you buy Cypherpunk Technologies stock or one of its competitors? MarketBeat compares Cypherpunk Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cypherpunk Technologies include AC Immune (ACIU), Galectin Therapeutics (GALT), Forte Biosciences (FBRX), Fulcrum Therapeutics (FULC), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.

How does Cypherpunk Technologies compare to AC Immune?

Cypherpunk Technologies (NASDAQ:CYPH) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Cypherpunk Technologies has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cypherpunk Technologies has higher earnings, but lower revenue than AC Immune. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
AC Immune	$3.70M	69.97	-$85.03M	-$0.82	N/A

In the previous week, Cypherpunk Technologies and Cypherpunk Technologies both had 1 articles in the media. AC Immune's average media sentiment score of 1.89 beat Cypherpunk Technologies' score of 1.89 indicating that AC Immune is being referred to more favorably in the news media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
AC Immune	Very Positive

Cypherpunk Technologies has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Cypherpunk Technologies' return on equity of -48.33% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
AC Immune	-1,788.02%	-125.26%	-40.85%

AC Immune has a consensus target price of $7.50, suggesting a potential upside of 194.70%. Given AC Immune's stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

AC Immune beats Cypherpunk Technologies on 10 of the 14 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Galectin Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

In the previous week, Galectin Therapeutics had 7 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 8 mentions for Galectin Therapeutics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Galectin Therapeutics' score of 0.95 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Galectin Therapeutics	Positive
Cypherpunk Technologies	Very Positive

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 121.33%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galectin Therapeutics' return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Summary

Galectin Therapeutics beats Cypherpunk Technologies on 8 of the 13 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Forte Biosciences?

Cypherpunk Technologies (NASDAQ:CYPH) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, Cypherpunk Technologies and Cypherpunk Technologies both had 1 articles in the media. Cypherpunk Technologies' average media sentiment score of 1.89 beat Forte Biosciences' score of 1.87 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Forte Biosciences	Very Positive

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Comparatively, 4.4% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cypherpunk Technologies' return on equity of -48.33% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Forte Biosciences	N/A	-106.17%	-85.50%

Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, suggesting that its share price is 187% more volatile than the broader market.

Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 218.59%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Forte Biosciences is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Summary

Forte Biosciences beats Cypherpunk Technologies on 7 of the 12 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Fulcrum Therapeutics?

Cypherpunk Technologies (NASDAQ:CYPH) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Fulcrum Therapeutics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Fulcrum Therapeutics' score of 1.30 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Fulcrum Therapeutics	Positive

Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the broader market.

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fulcrum Therapeutics' return on equity of -27.80% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

Cypherpunk Technologies has higher earnings, but lower revenue than Fulcrum Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Fulcrum Therapeutics	$80M	3.16	-$74.88M	-$1.15	N/A

Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 115.79%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Fulcrum Therapeutics beats Cypherpunk Technologies on 11 of the 14 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Cypherpunk Technologies has lower revenue, but higher earnings than Inhibikase Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	967.37	-$48.26M	-$0.43	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Inhibikase Therapeutics presently has a consensus price target of $5.40, suggesting a potential upside of 183.46%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Inhibikase Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Inhibikase Therapeutics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Inhibikase Therapeutics' score of 0.94 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibikase Therapeutics	Positive
Cypherpunk Technologies	Very Positive

Inhibikase Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Inhibikase Therapeutics' return on equity of -41.31% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Inhibikase Therapeutics beats Cypherpunk Technologies on 11 of the 15 factors compared between the two stocks.

Get Cypherpunk Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYPH vs. The Competition

Export

Metric	Cypherpunk Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$65.85M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-31.87	21.75	25.88	24.17
Price / Sales	N/A	330.97	548.17	99.03
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.35	8.31	10.82	6.38
Net Income	$4.82M	$23.92M	$3.58B	$337.00M
7 Day Performance	-13.40%	1.93%	1.92%	-0.23%
1 Month Performance	-43.56%	-0.41%	-0.24%	-1.40%
1 Year Performance	143.81%	65.22%	34.40%	27.76%

Cypherpunk Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYPH Cypherpunk Technologies	0.6468 of 5 stars	$0.64 +3.1%	N/A	+143.8%	$65.85M	N/A	N/A	40	Positive News Gap Down
ACIU AC Immune	2.8267 of 5 stars	$2.45 -3.5%	$7.50 +206.1%	+26.6%	$258.51M	$4.31M	N/A	140	Positive News
GALT Galectin Therapeutics	1.9641 of 5 stars	$4.23 +7.9%	$11.00 +160.0%	+113.3%	$258.16M	N/A	N/A	9	Gap Down High Trading Volume
FBRX Forte Biosciences	1.7706 of 5 stars	$18.71 +0.9%	$67.00 +258.1%	+71.7%	$257.44M	N/A	N/A	5	Positive News Gap Down
FULC Fulcrum Therapeutics	4.1912 of 5 stars	$3.61 -4.0%	$8.20 +127.1%	-46.5%	$250.54M	$80M	N/A	100	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYPH) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. ACIU, GALT, FBRX, FULC, and IKT

How does Cypherpunk Technologies compare to AC Immune?

Summary

How does Cypherpunk Technologies compare to Galectin Therapeutics?

Summary

How does Cypherpunk Technologies compare to Forte Biosciences?

Summary

How does Cypherpunk Technologies compare to Fulcrum Therapeutics?

Summary

How does Cypherpunk Technologies compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. ACIU, GALT, FBRX, FULC, and IKT

How does Cypherpunk Technologies compare to AC Immune?

Which has more risk & volatility, CYPH or ACIU?

Do institutionals and insiders believe in CYPH or ACIU?

Which has better earnings & valuation, CYPH or ACIU?

Does the media favor CYPH or ACIU?

Is CYPH or ACIU more profitable?

Do analysts rate CYPH or ACIU?

Summary

How does Cypherpunk Technologies compare to Galectin Therapeutics?

Which has preferable earnings & valuation, GALT or CYPH?

Which has more volatility and risk, GALT or CYPH?

Does the media refer more to GALT or CYPH?

Do institutionals & insiders believe in GALT or CYPH?

Do analysts prefer GALT or CYPH?

Is GALT or CYPH more profitable?

Summary

How does Cypherpunk Technologies compare to Forte Biosciences?

Does the media favor CYPH or FBRX?

Do insiders & institutionals have more ownership in CYPH or FBRX?

Is CYPH or FBRX more profitable?

Which has more risk & volatility, CYPH or FBRX?

Do analysts prefer CYPH or FBRX?

Which has higher earnings and valuation, CYPH or FBRX?

Summary

How does Cypherpunk Technologies compare to Fulcrum Therapeutics?

Does the media favor CYPH or FULC?

Which has more risk & volatility, CYPH or FULC?

Do institutionals and insiders hold more shares of CYPH or FULC?

Is CYPH or FULC more profitable?

Which has higher earnings & valuation, CYPH or FULC?

Do analysts prefer CYPH or FULC?

Summary

How does Cypherpunk Technologies compare to Inhibikase Therapeutics?

Which has preferable earnings and valuation, IKT or CYPH?

Do analysts prefer IKT or CYPH?

Does the media favor IKT or CYPH?

Which has more risk and volatility, IKT or CYPH?

Is IKT or CYPH more profitable?

Do insiders and institutionals hold more shares of IKT or CYPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools